88 related articles for article (PubMed ID: 28336829)
1. [The effect of oral calcimimetics on cardiovascular events.].
Hamano T
Clin Calcium; 2017; 27(4):529-535. PubMed ID: 28336829
[TBL] [Abstract][Full Text] [Related]
2. Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.
Moe SM; Chertow GM; Parfrey PS; Kubo Y; Block GA; Correa-Rotter R; Drüeke TB; Herzog CA; London GM; Mahaffey KW; Wheeler DC; Stolina M; Dehmel B; Goodman WG; Floege J;
Circulation; 2015 Jul; 132(1):27-39. PubMed ID: 26059012
[TBL] [Abstract][Full Text] [Related]
3. The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial.
Chang TI; Abdalla S; London GM; Block GA; Correa-Rotter R; Drüeke TB; Floege J; Herzog CA; Mahaffey KW; Moe SM; Parfrey PS; Wheeler DC; Dehmel B; Goodman WG; Chertow GM
J Hum Hypertens; 2016 Mar; 30(3):204-9. PubMed ID: 26040438
[TBL] [Abstract][Full Text] [Related]
4. The win ratio approach to analyzing composite outcomes: An application to the EVOLVE trial.
Abdalla S; Montez-Rath ME; Parfrey PS; Chertow GM
Contemp Clin Trials; 2016 May; 48():119-24. PubMed ID: 27080930
[TBL] [Abstract][Full Text] [Related]
5. Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial.
Wheeler DC; London GM; Parfrey PS; Block GA; Correa-Rotter R; Dehmel B; Drüeke TB; Floege J; Kubo Y; Mahaffey KW; Goodman WG; Moe SM; Trotman ML; Abdalla S; Chertow GM; Herzog CA;
J Am Heart Assoc; 2014 Nov; 3(6):e001363. PubMed ID: 25404192
[TBL] [Abstract][Full Text] [Related]
6. [Vascular Calcification - Pathological Mechanism and Clinical Application - . The effect of cinacalcet on vascular calcification].
Yokoyama K
Clin Calcium; 2015 May; 25(5):729-36. PubMed ID: 25926577
[TBL] [Abstract][Full Text] [Related]
7. The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.
Parfrey PS; Drüeke TB; Block GA; Correa-Rotter R; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Kubo Y; Dehmel B; Goodman WG; Chertow GM;
Clin J Am Soc Nephrol; 2015 May; 10(5):791-9. PubMed ID: 25710802
[TBL] [Abstract][Full Text] [Related]
8. Assessing the treatment effect in a randomized controlled trial with extensive non-adherence: the EVOLVE trial.
Kubo Y; Sterling LR; Parfrey PS; Gill K; Mahaffey KW; Gioni I; Trotman ML; Dehmel B; Chertow GM
Pharm Stat; 2015; 14(3):242-51. PubMed ID: 25851955
[TBL] [Abstract][Full Text] [Related]
9. Propensity score matching and persistence correction to reduce bias in comparative effectiveness: the effect of cinacalcet use on all-cause mortality.
Gillespie IA; Floege J; Gioni I; Drüeke TB; de Francisco AL; Anker SD; Kubo Y; Wheeler DC; Froissart M;
Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):738-47. PubMed ID: 26011775
[TBL] [Abstract][Full Text] [Related]
10. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
[TBL] [Abstract][Full Text] [Related]
11. Analyzing Health-Related Quality of Life in the EVOLVE Trial: The Joint Impact of Treatment and Clinical Events.
Briggs AH; Parfrey PS; Khan N; Tseng S; Dehmel B; Kubo Y; Chertow GM; Belozeroff V
Med Decis Making; 2016 Nov; 36(8):965-72. PubMed ID: 26987347
[TBL] [Abstract][Full Text] [Related]
12. [Retrospective assessment of effective and safety of cinacalcet for the treatment of secondary hyperparathyroidism depending on basal iPTH level].
Mercadal Orfila G; Blasco Mascaró I
Farm Hosp; 2012; 36(1):11-5. PubMed ID: 21514862
[TBL] [Abstract][Full Text] [Related]
13. Blood Calcification Propensity, Cardiovascular Events, and Survival in Patients Receiving Hemodialysis in the EVOLVE Trial.
Pasch A; Block GA; Bachtler M; Smith ER; Jahnen-Dechent W; Arampatzis S; Chertow GM; Parfrey P; Ma X; Floege J
Clin J Am Soc Nephrol; 2017 Feb; 12(2):315-322. PubMed ID: 27940458
[TBL] [Abstract][Full Text] [Related]
14. Cinacalcet for secondary hyperparathyroidism: from improved mineral levels to improved mortality?
Vervloet MG; du Buf-Vereijken PW; Potter van Loon BJ; Manamley N; Reichert LJ; Smak Gregoor PJ
Neth J Med; 2013 Sep; 71(7):348-54. PubMed ID: 24038560
[TBL] [Abstract][Full Text] [Related]
15. Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial.
Chertow GM; Correa-Rotter R; Block GA; Drueke TB; Floege J; Goodman WG; Herzog CA; Kubo Y; London GM; Mahaffey KW; Mix TC; Moe SM; Wheeler DC; Parfrey PS
Nephrol Dial Transplant; 2012 Jul; 27(7):2872-9. PubMed ID: 22529163
[TBL] [Abstract][Full Text] [Related]
16. Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trial.
Pun PH; Abdalla S; Block GA; Chertow GM; Correa-Rotter R; Dehmel B; Drüeke TB; Floege J; Goodman WG; Herzog CA; London GM; Mahaffey KW; Moe SM; Parfrey PS; Wheeler DC; Middleton JP
Hemodial Int; 2016 Jul; 20(3):421-31. PubMed ID: 26564024
[TBL] [Abstract][Full Text] [Related]
17. Administration of calcimimetics after dialysis: same effectiveness, better gastrointestinal tolerability.
Esteve Simo V; Moreno-Guzmán F; Martínez Calvo G; Fulquet Nicolas M; Pou Potau M; Macias-Toro J; Duarte-Gallego V; Saurina Sole A; Ramírez-de Arellano Serna M
Nefrologia; 2015; 35(4):403-9. PubMed ID: 26306967
[TBL] [Abstract][Full Text] [Related]
18. Chronic hemodialysis patients without marked elevation of intact parathyroid hormone are also good candidates for early intervention with cinacalcet.
Nishida H; Masakane I; Kudo K; Ito M; Tanida H; Koshika M; Nishida W; Tomita Y
Ther Apher Dial; 2013 Jun; 17(3):325-31. PubMed ID: 23735149
[TBL] [Abstract][Full Text] [Related]
19. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
[TBL] [Abstract][Full Text] [Related]
20. PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism.
Akizawa T; Kurita N; Mizobuchi M; Fukagawa M; Onishi Y; Yamaguchi T; Ellis AR; Fukuma S; Alan Brookhart M; Hasegawa T; Kurokawa K; Fukuhara S
Sci Rep; 2016 Apr; 6():19612. PubMed ID: 27071541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]